Skip to main content

Stephen J. Gardell, PhD

Stephen J. Gardell, PhD

Senior Investigator

Translational Research

Stephen Gardell

Overview

Dr. Gardell received his Ph.D. in Biochemistry from Cornell University Graduate School of Medical Sciences (NY, NY). His post-doctoral training in Molecule Biology was done at the University of California, San Francisco (UCSF), where he helped pioneer the use of site-directed mutagenesis to probe enzyme catalytic mechanisms. Dr. Gardell next spent 22 years in the drug discovery divisions of several major pharmaceutical companies (Merck, Bayer, Wyeth). The disease areas that were the target of his research pursuits included thrombosis, congestive heart failure, atherosclerosis, obesity, diabetes and Alzheimer’s disease. In 2009, Dr. Gardell joined the Sanford Burnham Prebys Medical Research Institute (SBP) in Orlando, Florida where he investigated an enzyme, nicotinamide phosphoribosyltransferase (NAMPT), which is the rate-determining step in NAD+ biosynthesis. He and his colleagues discovered small molecule activators of NAMPT that raise intracellular NAD+ levels, an effect with potential utility for a wide variety of diseases and healthy aging. While at SBP, Dr. Gardell also established a network of diverse technology cores and helped to direct the research operation. In May 2018, Dr. Gardell joined the TRI-MD in Orlando, Florida as a Senior Investigator where he continues his drug discovery research on NAMPT. In addition, Dr. Gardell established a Metabolomics Core at the TRI-MD which is a powerful technology platform to measure metabolites which serve to elucidate disease pathophysiology and unveil promising disease biomarkers..

Articles

Metabolic adaptation characterizes short-term resistance to weight loss induced by a low-calorie diet in overweight/obese individuals.

The American journal of clinical nutrition

2021

A Metabolomic Signature of Glucagon Action in Healthy Individuals With Overweight/Obesity

JOURNAL OF THE ENDOCRINE SOCIETY

2021

Optimization of a urea-containing series of nicotinamide phosphoribosyltransferase (NAMPT) activators

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

2021

Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a] pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

2021

Boosting NAD(+) with a small molecule that activates NAMPT

NATURE COMMUNICATIONS

2019

Metabolomics Analyses of Muscle Atrophy Induced by Hind Limb Unloading

METABOLOMICS: METHODS AND PROTOCOLS

2019

Measurement of Pyridine Nucleotides in Biological Samples Using LC-MS/MS

METABOLOMICS: METHODS AND PROTOCOLS

2019

Elevated Nicotinamide Phosphoribosyl Transferase in Skeletal Muscle Augments Exercise Performance and Mitochondrial Respiratory Capacity Following Exercise Training

FRONTIERS IN PHYSIOLOGY

2018

Impaired Mitochondrial Energetics Characterize Poor Early Recovery of Muscle Mass Following Hind Limb Unloading in Old Mice

JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

2018

Skeletal muscle overexpression of nicotinamide phosphoribosyl transferase in mice coupled with voluntary exercise augments exercise endurance

MOLECULAR METABOLISM

2018

Education & Training

Education

Cornell University, Graduate School of Medical Sciences, NY, NY

Associated Clinical Trials